The information herein is not intended to diagnose, treat, or cure any disease. This information should not be interpreted as medical advice or treatment.
Tiffany Devitt, the author of this report, holds stock in, is separately employed by, and serves on the Board of Directors of, CannaCraft, a commercial cannabis company. The views and opinions expressed in this report are those of the author and do not necessarily reflect the policies or positions of CannaCraft.
There are limitations to this observational study that warrant mention. Most significant is the way participants were selected; we recruited from people who visit the Project CBD website or social media sites, or subscribe to the Project CBD newsletter. This means that participants were interested in CBD as a treatment modality, and many had already found it to be helpful. This likely had the effect of increasing the proportion of patients who reported improvements and decreasing the proportion of patients reporting that their condition worsened.
The selection of patients may have also introduced systematic biases in other categories, though this is less clear. For example, since CBD is rarely a first-line treatment, patients who turn to CBD products may be more likely to respond poorly to other modalities. This sample bias cannot be distinguished from the data, and the data must be viewed with these qualifications in mind.
Finally, this study relies entirely on self-reported outcomes.